Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib

作者全名："Cai, Lu; Wei, Yi; Zhao, Min; Zhuo, Jia; Tao, Xiao; Lin, Mao"

作者地址："[Cai, Lu; Wei, Yi; Zhao, Min; Zhuo, Jia; Tao, Xiao; Lin, Mao] Chongqing Hosp Tradit Chinese Med, Dept Dermatol, Chongqing, Peoples R China; [Cai, Lu] Chongqing Med Univ, Chongqing, Peoples R China; [Lin, Mao] Sichuan Univ, West China Hosp, Dept Dermatol, Chengdu, Sichuan, Peoples R China"

通信作者："Lin, M (通讯作者)，Chongqing Hosp Tradit Chinese Med, Dept Dermatol, Chongqing, Peoples R China.; Lin, M (通讯作者)，Sichuan Univ, West China Hosp, Dept Dermatol, Chengdu, Sichuan, Peoples R China."

来源：FRONTIERS IN MEDICINE

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001087432700001

JCR分区：Q1

影响因子：3.1

年份：2023

卷号：10

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：alopecia areata; dupilumab; resistant to baricitinib; pediatric patients; Th1; Th2

摘要："Alopecia areata (AA) is a non-scarring hair loss disorder. Alopecia totalis (AT) and alopecia universalis (AU) are the severe subtypes of AA. Age of onset before 6 years of age, disease duration of more than 1 year, and extensive alopecia involving more than 50% of the scalp (including AT or AU) suggest a poorer prognosis. Topical corticosteroids are the preferred first-line treatment for pediatric AA. While some treatments, such as intralesional corticosteroids, systemic steroids, contact immunotherapy with squaric acid dibutyl ester, and JAK inhibitors, showed efficacy in adults with AA, their safety profiles limit their use in pediatric AA patients. Dupilumab is a biologic that effectively addresses the patho-physiology of Th2 allergic diseases, and treats atopic diseases by inhibiting the helper Th2 immune axis. AA has been reported to be significantly improved with dupilumab for atopic dermatitis (AD) in children and adults. We report hair regrowth over all of the scalp, eyebrows, and eyelashes after 10 months of dupilumab therapy in a 4-year-old AU patient resistant to baricitinib."

基金机构："This study was funded by ""Youth Qi Huang Scholar"" project by State Administration of TCM, National Natural Science Foundation of China (81402601) and Chongqing medical scientific research project (Joint project of Chongqing Health Commission and Science an [81402601]; State Administration of TCM, National Natural Science Foundation of China [2022DBXM007]; Chongqing medical scientific research project (Joint project of Chongqing Health Commission and Science and Technology Bureau)"

基金资助正文："This study was funded by ""Youth Qi Huang Scholar"" project by State Administration of TCM, National Natural Science Foundation of China (81402601) and Chongqing medical scientific research project (Joint project of Chongqing Health Commission and Science and Technology Bureau) (2022DBXM007)."